The purpose of this study is to assess the safety of etanercept liquid administered once weekly to subjects with RA.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Fulfill the 1987 American Rheumatism Association (ARA) criteria for RA
• Active RA at the time of enrollment, receipt of concomitant methotrexate at a dose of up to 25 mg a week is permitted
• Screening lab results must demonstrate: *AST and ALT less than or equal to 2 times the upper limit of normal hemoglobin greater than or equal to 8.5 g/dL; *Platelet count greater than or equal to 125,000/cm3; *White blood cell count (WBC) greater than or equal to 3500 cells/cm3; *Serum creatinine less than or equal to 2 mg/dL
• Before any study specific procedure is performed, the subject must provide informed consent for participation in the study

Exclusion Criteria:

• Previous receipt of etanercept
• Receipt of antibody to (tumor necrosis factor) TNF alpha or other TNF inhibitors within 90 days of Day 1
• Currently enrolled in other investigational device or drug trials, or participation in investigational trial within the past 30 days
• Receipt of intra-articular corticosteroids within 14 days prior to Day 1
• Receipt of any disease-modifying anti-rheumatic drugs (DMARDs) within 28 days of Day 1
• Receipt of cyclophosphamide within 6 months of Day 1
• Concomitant corticosteroids greater than 10 mg/day of prednisone (or equivalent) during 14 days prior to Day 1
• Dose of nonsteroidal anti-inflammatory drug (NSAID) must be stable for 14 days prior to Day 1 and must not exceed the recommended dose in the product information sheet
• Subject is not using adequate contraception
• Subject is pregnant or breast-feeding
• Subject has significant concurrent medical disease